The Omnilink Elite system is the latest addition to Abbott’s U.S. portfolio of endovascular products for the treatment of peripheral artery disease. The Omnilink Elite stent is based on the MULTI-LINK stent design with a cobalt chromium alloy, according to the company.
“Abbott is dedicated to improving the lives of patients with PAD by providing physicians with the most innovative therapies for treatment of this debilitating disease,” said Charles A. Simonton, MD, FACC, FSCAI, divisional vice president, medical affairs, and chief medical officer, Abbott Vascular, in the release. “The approval of Omnilink Elite and the recent FDA approval of Absolute Pro [vascular self-expanding stent system] add to Abbott’s already robust portfolio of advanced endovascular products for the treatment of PAD.”
Abbott is headquartered in Chicago.
Related Articles on FDA Clearances:
Bausch + Lomb and Technolas Perfect Vision Receive FDA Clearance for Femtosecond Laser Platform
NeuroMetrix Receives FDA Clearance for Electrical Nerve Stimulator
Actuated Medical Receives FDA Clearance for Tubeclear System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.